Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MRK Merck & Co., Inc. weekly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexDJIA S&P500 P/E25.52 EPS (ttm)3.18 Insider Own0.10% Shs Outstand2.59B Perf Week2.39%
Market Cap209.68B Forward P/E15.26 EPS next Y5.31 Insider Trans-29.71% Shs Float2.57B Perf Month8.42%
Income8.40B PEG2.61 EPS next Q1.15 Inst Own78.10% Short Float0.56% Perf Quarter0.31%
Sales43.07B P/S4.87 EPS this Y27.80% Inst Trans-0.55% Short Ratio1.37 Perf Half Y6.12%
Book/sh10.65 P/B7.61 EPS next Y11.98% ROA10.00% Target Price88.07 Perf Year38.61%
Cash/sh3.40 P/C23.83 EPS next 5Y9.76% ROE28.20% 52W Range58.03 - 83.85 Perf YTD6.03%
Dividend2.20 P/FCF68.93 EPS past 5Y9.60% ROI11.20% 52W High-2.72% Beta0.61
Dividend %2.72% Quick Ratio1.10 Sales past 5Y-0.80% Gross Margin69.10% 52W Low40.58% ATR1.45
Employees69000 Current Ratio1.40 Sales Q/Q7.80% Oper. Margin24.40% RSI (14)64.74 Volatility1.54% 1.72%
OptionableYes Debt/Eq0.94 EPS Q/Q312.30% Profit Margin19.50% Rel Volume0.46 Prev Close81.02
ShortableYes LT Debt/Eq0.83 EarningsApr 30 BMO Payout62.30% Avg Volume10.46M Price81.57
Recom1.80 SMA203.73% SMA502.56% SMA2008.35% Volume337,868 Change0.68%
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
May-24-19 08:25AM  Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics Zacks
May-23-19 04:15PM  Synlogic (SYBX) Enters Cancer Collaboration with Roche Zacks
08:20AM  J&J's Invokana sNDA Gets Priority Review Status From FDA Zacks
May-22-19 05:13PM  Array BioPharma Gains on Colorectal Cancer Study Success Zacks
12:38PM  Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond Benzinga
09:38AM  Company News For May 22, 2019 Zacks
09:37AM  Merck to Buy Private Cancer Drugmaker Peloton Therapeutics Zacks
08:00AM  Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings Business Wire
May-21-19 05:07PM  Merck Snaps Up Cancer Drugmaker Peloton Therapeutics Barrons.com
04:26PM  Dow logs 200-point gain as demand for tech, energy stocks overshadow trade angst MarketWatch
01:20PM  These 3 Major Drug Manufacturers Are Strong Performers GuruFocus.com
10:56AM  After filing an IPO, Dallas company to sell to Merck for $1.05 billion American City Business Journals
10:47AM  Merck buys Peloton to expand its kidney cancer treatment portfolio Reuters
10:39AM  Merck to Buy Peloton for Up to $2.2 Billion, Day Before IPO Bloomberg
10:39AM  Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B Benzinga
09:37AM  Merck to Acquire Peloton Therapeutics for About $1B in Cash TheStreet.com
09:00AM  Merck to buy cancer drug developer in deal that could be worth more than $2B American City Business Journals
08:46AM  Merck's Keytruda Fails in Late-Stage Breast Cancer Study Zacks
06:55AM  Merck to acquire Peloton Therapeutics for upfront payment of $1.05 billion in cash MarketWatch
06:45AM  Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline Business Wire
04:24AM  Stocks - Kohls, JC Penny, Tesla Fall Premarket; Boeing Rises Investing.com
May-20-19 05:44PM  Stocks making the biggest moves after hours: GM, Snap, Merck and more CNBC
05:23PM  Merck's Keytruda fails as monotherapy in breast cancer study Reuters
05:08PM  Merck shares slip as Keytruda fails another clinical trial MarketWatch
04:59PM  Merck's Keytruda fails as monotherapy in breast cancer study Reuters
04:30PM  Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer Business Wire
02:14PM  U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits Reuters
10:21AM  U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drug Reuters
09:15AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
09:02AM  AbbVie's Brain Cancer Candidate Fails in Phase III Study Zacks
08:11AM  CPPIB buys partial Keytruda royalty interest from British charity LifeArc Reuters
07:46AM  CPPIB buys partial Keytruda royalty interest from British charity LifeArc Reuters
05:05AM  Why Stock Buybacks Are Soaring Near Record Highs Amid Trade War Investopedia
May-17-19 08:35AM  Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs Zacks
May-16-19 10:12PM  Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles Reuters
06:35PM  Bayer bets on 'silver bullet' defence in Roundup litigation; experts see hurdles Reuters
05:56PM  Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles Reuters
05:56PM  Bayer bets on 'silver bullet' defence in Roundup litigation; experts see hurdles Reuters
05:44PM  Sarah Ketterer's Top 5 New Buys GuruFocus.com
04:35PM  ImmunoGen Plunges as FDA Recommends New Study for Lead Drug Zacks
08:24AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
May-15-19 05:00PM  New Research from Mercks Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting Business Wire
09:27AM  Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer Zacks
08:45AM  4 Dow Stocks to Buy on the Dip Despite Market Volatility Zacks
07:50AM  The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi Benzinga
07:12AM  How Do Analysts See Merck & Co., Inc. (NYSE:MRK) Performing In The Year Ahead? Simply Wall St.
May-14-19 09:46AM  Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer Zacks
06:57AM  Merck KGaA sees currencies supporting 2019 outlook Reuters
01:20AM  Merck KGaA sees currencies supporting 2019 outlook Reuters
May-13-19 09:17AM  What's in Store for Affimed (AFMD) This Earnings Season? Zacks
May-10-19 02:41PM  Endo (ENDP) Q1 Earnings & Revenues Beat Estimates Zacks
07:34AM  Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug Zacks
May-09-19 02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
01:28PM  Why this former health care CEO thinks this Uber board member is crucial to its success Yahoo Finance Video
07:00AM  Katie Couric Joins Merck and Cancer Advocates to Support Patients and Caregivers Through the Expansion of Your Cancer Game Plan (YCGP) Business Wire
May-08-19 12:06PM  Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates Zacks
10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
09:56AM  Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates Zacks
09:01AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Merck, Charter Communications, Anthem and Norfolk Southern Zacks
09:00AM  Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants Business Wire
May-07-19 03:40PM  Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications Zacks
06:45AM  Mercks BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimers Disease Dementia Business Wire
May-06-19 10:43AM  Here are the biggest stock-market losers after Trump threatens more tariffs MarketWatch
09:44AM  ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 Zacks
09:21AM  The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo Zacks
06:37AM  Two Healthcare Stocks in the XLV Fund Stand Out InvestorPlace
May-03-19 06:10AM  Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod Zacks
05:13AM  Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress Zacks
01:08AM  Edited Transcript of MRK earnings conference call or presentation 30-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
May-02-19 03:50PM  Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch
02:46PM  Merck Stock Bounces Back Thanks to a 'Golden Cross' Investopedia
12:43PM  Federal Reserve Chair Jerome Powell may have just killed the stock market melt-up Yahoo Finance
12:08PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade Moody's
09:15AM  Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice Zacks
May-01-19 06:56PM  The Top Pharma Stocks for 2019 Investopedia
04:09PM  Merck steps up U.S. measles vaccine production with increased demand Reuters
01:55PM  Profit from Earnings Volatility With This Biotech Stocks Pairs Trade InvestorPlace
08:40AM  Company News For May 1, 2019 Zacks
Apr-30-19 06:25PM  US STOCKS-S&P 500 posts best four-month run in nearly 9 years; Apple jumps after hours Reuters
06:16PM  Merck & Co Inc (MRK) Q1 2019 Earnings Call Transcript Motley Fool
06:16PM  Wall Street Mostly Higher on Tuesday GuruFocus.com
04:22PM  S&P 500 ekes out third straight record close; Nasdaq retreats after Google revenue miss MarketWatch
03:18PM  Trump, Democratic leaders to meet on drug prices soon -White House Reuters
03:00PM  What You Need to Know About Merck's Great Q1 Earnings Results Motley Fool
01:28PM  US STOCKS-Wall Street's record run hits snag after Alphabet tumbles Reuters
11:58AM  US STOCKS-Wall Street stumbles after record run as Alphabet slides Reuters
11:50AM  Merck Smashes Q1 Earnings Estimate, Boosts 2019 Outlook, as Keytruda Sales Surge TheStreet.com
11:37AM  Merck raises full-year forecasts as vaccines power profit beat Reuters
10:54AM  10 Workhorse Health Care Stocks That Never Break a Sweat Kiplinger
10:51AM  Merck 1Q net quadruples as cancer drug, vaccine sales soar Associated Press
10:47AM  Merck raises full-year forecasts as vaccines power profit beat Reuters
10:46AM  Big Pharma Puts the Price Squeeze on Itself Bloomberg
10:30AM  US STOCKS-Wall Street pauses after record run as Alphabet tumbles Reuters
10:24AM  GEs free-cash improvement might not be all that, Apple still has a China problem MarketWatch
10:20AM  Merck and Pfizer Stock Rise but Eli Lilly Slips as Big Pharma Earnings Roll in Barrons.com
09:52AM  Fed and tech stocks could crack the market rally, warns Wall Street strategist MarketWatch
09:48AM  Merck (MRK) Beats on Q1 Earnings & Sales as Keytruda Shines Zacks
09:08AM  Merck raises full-year forecasts as vaccines power profit beat Reuters
08:30AM  Merck raises full-year forecasts as vaccines power profit beat Reuters
07:12AM  Is Merck & Co., Inc.'s (NYSE:MRK) CEO Being Overpaid? Simply Wall St.
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Intec Pharma Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
open in yahoo | open in reuters | open in google